Active Biotech AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.activebiotech.com
A Study of Laquinimod Eye-drops in Healthy Participants
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 54
- Registration Number
- NCT05187403
- Locations
- 🇦🇹
Clinical trial center at Medical University Vienna, Vienna, Austria
An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 9
- Registration Number
- NCT01487551
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 1245
- Registration Number
- NCT01234311
A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 6
- Registration Number
- NCT01048203
- Locations
- 🇸🇪
JJ Berzelius Clinical Research Center AB, Berzelius Science Park, Linköping, Sweden
Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT00997100
- Locations
- 🇸🇪
Lars Rönnblom M.D., Uppsala, Sweden
🇸🇪Iva Gunnarsson M.D., Stockholm, Sweden
🇩🇰Soren Jacobsen, Copenhagen, Denmark
Efficacy Study of ABR-215050 to Treat Prostate Cancer
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 206
- Registration Number
- NCT00560482
- Locations
- 🇺🇸
Staten Island Urological Research, PC, Staten Island, New York, United States
🇺🇸Southeastern Resarch Group, Inc., Tallahassee, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 526
- Registration Number
- NCT00420888
- Locations
- 🇷🇴
Oncomed SRL, Timisoara, Romania
🇺🇦Ivano-Frankovsk Regional Oncology Center, Ivano-Frankovsk, Ukraine
🇷🇴E-URO Medical Center, Cluj Napoca, Romania
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT00132379
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇰Onkologisk Klinik, Rigshospitalet, Copenhagen, Denmark
🇷🇺City Multifield Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery, St. Petersburg, Russian Federation
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-18
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 44
- Registration Number
- NCT00056537
- Locations
- 🇳🇴
Det Norske Radiumhospitalet, Oslo, Norway
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇬🇧Paterson Institute for Cancer Research, Christie Hospital NHS Trust and Research Institute, Manchester, United Kingdom